Scott Huennekens

About Scott Huennekens

Scott Huennekens is President and CEO of Volcano Therapeutics. Scott Huennekens has served as our President and Chief Executive Officer and as a member of our board of directors since April 2002. From January 2000 to March 2002, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company. Mr. Huennekens holds a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard University.

Related Entities

Volcano Announces Agreement to Acquire CardioSpectra
54 articles also mentioned Volcano

Volcano Announces Agreement to Acquire CardioSpectra
21 articles also mentioned CardioSpectra

Volcano Announces Acquisition of Axsun Technologies, Inc. for $21.5M
19 articles also mentioned Axsun Technologies

Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
10 articles also mentioned Siemens

Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
7 articles also mentioned John Dahldorf

CardioSpectra gets boost in OCT development from Volcano
6 articles also mentioned Thomas E. Milner

Quotes

“ Our technology innovation, market development, clinical and product initiatives have fueled our growth during 2009 and leave us well positioned for a strong 2010 marked by excellent revenue growth and GAAP profitability. ”
In Volcano Reports 44 Percent Increase in Fourth Quarter Revenues
“ Volcano is excited to fortify its commitment to be the leading and most-trusted partner for physicians when addressing patients with complex disease states that require thrombus aspiration. ”
In Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract Thrombus Aspiration Catheter
“ Reaching this milestone as quickly as we have is a clear demonstration of the strong demand for our diverse PCI guidance technology....Despite the challenging healthcare and economic environment in the U.S., Volcano has placed more systems in the past 12 months than at anytime in our history, and by our estimate, capturing more than 70% of all new IVUS systems placed in U.S. hospitals during this period. ”
In Volcano Announces Installed Base Growth Milestone
“ In addition to experiencing a very solid financial performance during the quarter, we completed our transition from our distributor relationship with Goodman to a direct sales effort in Japan and had new data demonstrating the value of our offerings presented at the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting. ”
In Volcano Reports 22 Percent Increase in Third Quarter Revenues
“ Angiography alone is not enough and more and more clinical data continues to support that conclusion. ”
In Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcano's VH(R) IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
“ Volcano had an excellent quarter with strong growth in our core intravascular ultrasound and functional measurement businesses. ”
In Volcano cuts Q2 loss, revenue increases
“ Volcano had an excellent quarter with strong growth in our core intravascular ultrasound (IVUS) and functional measurement (FM) businesses and key geographies. IVUS disposable revenues in the quarter were $31.8 million, a record quarter for this business, and a 26 percent increase over the second quarter a year ago. FM revenues in the quarter were a record $7.2 million, with FM disposable revenues increasing 75 percent over the second quarter a year ago. In addition, we continued our successful IVUS/FM console placement initiatives, placing 233 consoles versus 178 a year ago, an increase of 31 percent. ”
In Volcano Reports 30 Percent Increase in Second Quarter Revenues
“ We are delighted to be completing this transition nearly a year ahead of our original timetable...Japan is the largest IVUS market in the world. Given recent clinical data, Japan also represents a great market opportunity for our FM offerings, as well as the products in our pipeline, such as image-guided therapy, Optical Coherence Tomography (OCT), Forward-Looking IVUS and Impact micro-catheters. By going direct, we hope to replicate in Japan the market share gains we have achieved in our other key geographies, such as the United States and Europe. ”
In Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
“ We know from our many years of experience in the IVUS imaging business that simplicity, reliability and cost-effectiveness are just as important to the medical field as imaging performance and resolution. To date, development of the OCT market has been hampered because the lasers used were expensive, cumbersome and not as robust. With our new Axsun laser powering the leading OCT systems, Volcano is enabling a true breakthrough in the industry - a breakthrough that is the result of a 10 year development effort and an investment of over $150 million dollars. We're proud to be a driver of this field and again the technology leader in this important new area of medical imaging. Lightlab's decision to incorporate an Axsun laser into its systems further supports the potential of this technology. ”
In Volcano Announces OCT Activities at EuroPCR 2009
“ To our knowledge, Volcano's Axsun laser is by far the smallest and simplest high performance external cavity laser available in the world. This miniaturization is expected to provide huge benefits to the medical community in terms of system reliability, form-factor flexibility and ruggedness. In fact, our quality engineers are testing to Mean Time Between Failure (MTBF) rates measured in decades, not days or years. Despite its ultra small size, this new class of lasers is able to provide extraordinary levels of speed and performance, which should result in superior image quality and allow for very rapid image acquisition times and streamlined procedural workflows. ”
In Volcano Announces OCT Activities at EuroPCR 2009